MedTrace Logo

The Efficacy of Different Bupivacaine Concentrations in Pediatric Patients Undergoing Transversus Abdominis Plane Block

NCT04202367 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2019-12-17

No results posted yet for this study

Summary

This study is designed to compare the analgesic efficacy of different bupivacaine concentrations in pediatric patients undergoing ultrasound-guided transversus abdominis plane (TAP) block for unilateral inguinal hernia repair. In recruited 74 patients; Group 1 (n:37) received 1 mg/kg bupivakain 0.25% and Group 2 (n: 37) received 1 mg/kg bupivakain 0.125% for ultrasound-guided TAP block following standard general anaesthesia induction. FLACC (Face, Legs, Activity, Cry, Consolability) behavioral pain assessment scale was used for evaluating patients' postoperative pain levels at 15-, 30-, 45-minute and 1-, 2-, 6-, 24-hour. Tramadol 1 mg/kg was administered intravenously as rescue analgesic when FLACC score was ≥4. Total analgesic requirement, length of hospital stay and side effects were recorded.

Conditions

  • Transversus Abdominis Plane Block

Interventions

DRUG

1 mg.kg-1 bupivacaine 0.25%

Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.

DRUG

1 mg.kg-1 bupivacaine 0.125%

Ultrasound-guided transversus abdominis plane block for unilateral inguinal hernia repair surgery.

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Meltem Savran Karadeniz, Assoc. Prof · Istanbul University

  • Emine Aysu Salviz, Assoc. Prof · Istanbul University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2017-06-01
Completion
2017-07-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04202367 on ClinicalTrials.gov